3716 logo

Cenra Inc.TWSE:3716 Stock Report

Market Cap NT$4.7b
Share Price
NT$32.20
NT$81.08
60.3% undervalued intrinsic discount
1Y-7.7%
7D-2.4%
Portfolio Value
​
View

Cenra Inc.

TWSE:3716 Stock Report

Market Cap: NT$4.7b

Cenra (3716) Stock Overview

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. More details

3716 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends3/6

Rewards

Trading at 60.3% below our estimate of its fair value

Risk Analysis

Earnings have declined by 13.5% per year over past 5 years


3716 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 73.2% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.4k
21
2
48
20d ago

Cenra Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cenra
Historical stock prices
Current Share PriceNT$32.20
52 Week HighNT$38.70
52 Week LowNT$32.00
Beta0
1 Month Change-2.57%
3 Month Change-5.01%
1 Year Change-7.74%
3 Year Changen/a
5 Year Changen/a
Change since IPO-22.87%

Recent News & Updates

Recent updates

Shareholder Returns

3716TW PharmaceuticalsTW Market
7D-2.4%0.6%3.8%
1Y-7.7%12.6%93.1%

Return vs Industry: 3716 underperformed the TW Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: 3716 underperformed the TW Market which returned 93.1% over the past year.

Price Volatility

Is 3716's price volatile compared to industry and market?
3716 volatility
3716 Average Weekly Movement1.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.9%
10% most volatile stocks in TW Market11.9%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 3716 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 3716's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1952n/aHou-Kai Wangwww.cenra.com

Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It offers active pharmaceutical ingredients, generic drugs for human use, over to the counter drugs, self-care products for the prevention of diseases, home care and cosmetics, and animal healthcare products. The company is also involved in the research and development, contracting manufacturing and international, and senior care services, as well as distributes and sells pharmaceutical brands.

Cenra Inc. Fundamentals Summary

How do Cenra's earnings and revenue compare to its market cap?
3716 fundamental statistics
Market capNT$4.71b
Earnings (TTM)NT$300.07m
Revenue (TTM)NT$8.57b
15.7x
P/E Ratio
0.5x
P/S Ratio

Is 3716 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3716 income statement (TTM)
RevenueNT$8.57b
Cost of RevenueNT$5.25b
Gross ProfitNT$3.32b
Other ExpensesNT$3.02b
EarningsNT$300.07m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)2.05
Gross Margin38.71%
Net Profit Margin3.50%
Debt/Equity Ratio34.5%

How did 3716 perform over the long term?

See historical performance and comparison

Dividends

3.1%
Current Dividend Yield
42%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/23 20:30
End of Day Share Price 2026/04/23 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cenra Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wei Zheng KitCitigroup Inc
Yuan LuKGI Securities Co. Ltd.
Evana ChenMasterlink Securities Corp.